Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib adjuvant therapy after hepatectomy in high‑risk hepatocellular carcinoma
ChiCTR2000034143Phase 4Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: 2-year recurrence-free survival rate. Started Jun 2020; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000034143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034143.